Nocturia Market , By Drug Class (Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin), Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin), Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium), Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron), Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing), and Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)), By Route of Administration (Oral, Intranasal, Sublingual/orodispersible, and Parenteral and other systemic routes), By Dosage Form (Immediate-release tablets or capsules, Modified/extended-release oral formulations, Orodispersible tablets or film, Nasal sprays or drops, and Injectable formulations), By Mechanism of Action (Vasopressin Receptor Agonists, Smooth Muscle Relaxants, Muscarinic Receptor Blockers, Beta-3 Receptor Stimulants, Prostate-Targeted Relaxants, and Fluid-Regulation Modulators), By Prescription Type (Prescription-Only Medicines (Rx) and Over-the-Counter Options (OTC)), By Age Group (Adult and Geriatric), By Gender (Male and Female), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals, Specialty urology clinics, Long-term care and nursing facilities, and Home-care and self-administration settings), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Growth Trends and Forecasts (2025-2032)